Last Updated: November 16, 2026

Details for Patent: 11,957,674

« Back to Dashboard


Which drugs does patent 11,957,674 protect, and when does it expire?

Patent 11,957,674 protects PALSONIFY and is included in one NDA.

This patent has thirty-two patent family members in twenty-seven countries.

Summary for Patent: 11,957,674
Title:Formulations of a somatostatin modulator
Abstract:Described herein are formulations of a somatostatin modulator, methods of making such formulations, and methods of using such formulations in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
Inventor(s):Gerald Burke, Ian Yates, Hannah Bulovsky, Kyle Kyburz, Clayton Tyler
Assignee: Crinetics Pharmaceuticals Inc
Application Number:US17/584,225
Patent Claim Types:
see list of patent claims
Use; Composition;
Patent landscape, scope, and claims:

US Patent 11,957,674: Paltusotine Claims, Exclusivity, Formulation Scope, and Generic Risk

US Patent No. 11,957,674 protects oral administration of paltusotine, an oral growth hormone receptor 2 agonist, for suppressing growth hormone and related hormones. The patent is directed primarily to dosing conditions, endocrine indications, dose range, and amorphous solid-dispersion formulations.

The commercial risk is concentrated in claims 1, 2, 4-6 and 15 for ordinary oral use, and in claims 7-14 for specific spray-dried formulations containing HPMCAS or PVP/VA polymers. A generic or follow-on product would need to avoid the claimed compound, the claimed empty-stomach dosing condition, the specified formulation architecture, or the covered endocrine treatment indications.

What drug does US Patent 11,957,674 protect?

The claimed active pharmaceutical ingredient is paltusotine, identified in the patent by its chemical name:

3-[4-(4-amino-piperidin-1-yl)-3-(3,5-difluoro-phenyl)-quinolin-6-yl]-2-hydroxy-benzonitrile.

The claims also cover pharmaceutically acceptable salts and, in specified claims, solvates. The hydrochloride salt is the principal form described in the claims.

Item Scope
Active ingredient Paltusotine
Principal salt Paltusotine monohydrochloride
Dosage form Oral pharmaceutical composition
Primary biological effect Suppression of GH, insulin, glucagon, IGF-1, prolactin, or combinations
Core disease indications Acromegaly and neuroendocrine tumors
Administration condition Empty stomach, at least 30 minutes before a meal
Frequency Once daily in dependent claims
Claimed dose Approximately 20 mg to approximately 60 mg
Formulation technology Spray-dried dispersion
Key polymers HPMCAS and PVP/VA
Patent US 11,957,674 B2
Patent holder Crinetics Pharmaceuticals, Inc., based on the public patent record

The patent claims treatment methods rather than a new molecular entity. Its commercial value therefore depends on use of paltusotine in the covered endocrine indications and on whether the marketed product uses the claimed formulation and dosing instructions.

What does independent claim 1 cover?

Claim 1 requires all of the following elements:

  1. A human subject.
  2. Oral administration.
  3. Administration on an empty stomach.
  4. Administration at least 30 minutes before a meal.
  5. A pharmaceutical composition containing a therapeutically effective amount of paltusotine, or an acceptable salt or solvate.
  6. Suppression of GH, insulin, glucagon, IGF-1, prolactin, or a combination of those hormones.

The claim is broad in its biological endpoint. It does not require acromegaly, neuroendocrine tumors, once-daily dosing, a specific tablet composition, a particular dose, or a specific polymer.

That breadth creates two important consequences.

First, a product can potentially fall within claim 1 even if its label does not expressly identify every hormone endpoint, provided the claimed treatment method is practiced and the product is used under the claimed conditions.

Second, claim 1 is narrower than a general composition or compound claim. A product containing paltusotine but labeled for administration with food, or without a 30-minute pre-meal instruction, would present a different infringement analysis. Actual prescribing and patient use could still matter for induced-infringement theories.

Which claims cover acromegaly and neuroendocrine tumors?

Claims 2 and 3 add the disease limitation:

Claim Disease limitation
Claim 2 Human has acromegaly
Claim 3 Human has neuroendocrine tumors

Claim 2 is commercially more important if the approved product is indicated for acromegaly. Claim 3 is relevant to development programs involving hormone-secreting neuroendocrine tumors.

These claims are method-of-use claims. They do not require a particular tumor subtype, prior treatment, biomarker, baseline hormone level, or treatment duration. Their scope may therefore extend across multiple patient populations, subject to the ordinary rules governing claim construction and written-description support.

What dose and dosing schedule are protected?

Claims 4, 5, 6 and 15 create a dose-and-administration cluster.

Claim Limitation
Claim 4 Amount equivalent to approximately 20 mg to approximately 60 mg of paltusotine monohydrochloride
Claim 5 Once-daily administration
Claim 6 Once daily with a glass of water, on an empty stomach, at least 30 minutes before a meal
Claim 15 Administration of approximately 20 mg to approximately 60 mg of paltusotine monohydrochloride

Claim 6 is the most commercially specific dosing claim. It combines active ingredient, frequency, water administration and pre-meal timing. Claim 15 is broader than claim 6 because it does not repeat the fasting or water limitations.

The use of "equivalent to" in claim 4 is intended to capture non-hydrochloride forms or different salt or solvate forms measured against the stated amount of the monohydrochloride. Generic developers would need to assess whether their proposed strength, salt form and label fall within that equivalence limitation.

A 20 mg, 40 mg or 60 mg tablet administered once daily before breakfast would likely be the highest-risk design if it contains paltusotine and is labeled for acromegaly.

What formulations are protected by US 11,957,674?

Claims 7-14 protect formulations built around a spray-dried dispersion, or SDD. The formulation claims require a defined relationship between the active ingredient, polymer matrix and excipients.

HPMCAS and PVP/VA polymer claims

The two principal polymer alternatives are:

  • Hydroxypropyl methylcellulose acetate succinate, or HPMCAS.
  • Polyvinylpyrrolidone polyvinyl acetate copolymer, or PVP/VA.

Claims 7 and 8 cover either polymer system. Claims 9 and 10 focus on HPMCAS. Claims 11-14 focus on PVP/VA.

The claimed active-to-polymer ratio is approximately 15/85 to 35/65. This is a material limitation. A formulation containing paltusotine with a polymer ratio outside that range may avoid the literal ratio limitation, although the formulation could still raise equivalence issues depending on the patent’s construction and prosecution history.

Claim Formulation scope
Claim 7 20%-40% SDD; 60%-80% excipients; optional coating below 5%
Claim 8 SDD active-to-polymer ratio of about 15/85 to 35/65; HPMCAS or PVP/VA
Claim 9 20%-40% SDD using paltusotine HCl and HPMCAS
Claim 10 Claim 9 plus specified excipient category and optional coating
Claim 11 20%-40% SDD using paltusotine HCl and PVP/VA
Claim 12 Claim 11 plus specified excipient category and optional coating
Claim 13 20%-35% SDD using a 15/85 or 35/65 PVP/VA ratio
Claim 14 Claim 13 plus a defined excipient list

Excipients covered by claims 7-14

The claims identify excipient classes and, in claim 14, specific materials:

  • Microcrystalline cellulose
  • Mannitol
  • Pregelatinized starch
  • Croscarmellose sodium
  • Crospovidone
  • Sodium chloride
  • A 1:1 sodium chloride/potassium chloride mixture
  • Silicon dioxide
  • Magnesium stearate
  • Film-coating agents

The formulation claims are cumulative. A product must satisfy the parent method claim and the additional composition limitations. A tablet using paltusotine but a conventional crystalline formulation, without the claimed SDD structure, would not literally satisfy claims 7-14.

How strong is the patent estate?

The patent estate is strongest where the commercial product matches the patent’s dosing instructions and formulation architecture.

Risk category Assessment
Core oral use of paltusotine High
Acromegaly treatment High if labeled for that indication
Once-daily dosing High where the label specifies once daily
20-60 mg dose range High for standard commercial strengths
Empty-stomach administration High if included in labeling
HPMCAS SDD High if used in the marketed tablet
PVP/VA SDD High if used in the marketed tablet
Alternative polymer formulation Lower under literal infringement analysis
Non-oral administration Outside the express scope of claim 1
Different active compound Outside the claim
Biosimilar competition Not applicable

The principal vulnerability is that many claims are method claims tied to observable clinical instructions. That makes infringement easier to evaluate from product labeling, prescribing information, clinical protocols and marketing materials. The formulation claims are narrower but can provide a second layer of protection if the commercial tablet uses one of the claimed SDD systems.

The main validity pressure points would likely involve written description, enablement, obviousness of the dosing regimen, obviousness of the formulation composition, and whether the claimed fasting instruction produces a patentable clinical or pharmacokinetic distinction over prior art.

When does US Patent 11,957,674 expire?

The exact expiration date depends on the patent’s earliest effective nonprovisional filing date, patent-term adjustment, any terminal disclaimer and any patent-term extension. A US utility patent normally receives a term of 20 years from the earliest effective nonprovisional filing date, subject to those adjustments (35 U.S.C. § 154).

The patent’s issue date was May 7, 2024. The issue date does not control expiration. For commercial analysis, the relevant date is the patent’s adjusted expiration date shown in USPTO records and, if listed, FDA Orange Book records.

The patent should be treated as a late-2030s exclusivity asset based on the underlying paltusotine development timeline, but an exact expiration date should not be inferred solely from the patent number or issue date.

What is the FDA and Orange Book status?

Paltusotine is an orally administered small-molecule SSTR2 agonist developed by Crinetics Pharmaceuticals for acromegaly. The principal FDA pathway is an NDA, not a biologics license application.

The product is therefore subject to generic-drug competition under the Hatch-Waxman framework. A future abbreviated new drug application could use an ANDA pathway if the reference product and proposed generic satisfy the applicable requirements.

Regulatory issue Analysis
Regulatory pathway NDA and potential future ANDA competition
Product type Small molecule
Biosimilar pathway Not applicable
Patent listing Depends on FDA Orange Book submission and accepted listing
Likely challenge route Paragraph IV certification
Key patent categories Method of use, dose, formulation
Reference-product risk Label carve-out and induced-infringement analysis

A method-of-use patent may be listed in the Orange Book if it claims an approved use and meets FDA listing requirements. A generic applicant could issue a Paragraph IV certification against a listed patent, asserting that the patent is invalid, unenforceable or not infringed. The patent holder could then file an infringement action within the statutory period, potentially triggering a 30-month stay under 21 U.S.C. § 355(j)(5)(B)(iii).

Which companies are challenging paltusotine exclusivity?

No public Paragraph IV litigation or settlement involving US 11,957,674 is established by the claim information alone. The likely challengers would be generic drug companies with experience in complex oral formulations and ANDA litigation, particularly companies capable of developing amorphous solid dispersions and characterizing polymer-based dissolution systems.

Potential competitive categories include:

  • Large generic manufacturers with endocrine portfolios.
  • Specialty generic companies targeting complex oral dosage forms.
  • Contract development and manufacturing organizations supporting non-infringing formulations.
  • Developers of alternative oral somatostatin-pathway products.

The principal design-around options would be:

  1. Use of a polymer other than HPMCAS or PVP/VA.
  2. Use of a non-SDD formulation.
  3. A drug product not labeled for the claimed endocrine indication.
  4. A dosing instruction that does not require administration at least 30 minutes before a meal.
  5. A dose outside the 20-60 mg range, if clinically and regulatorily feasible.
  6. A different salt, solvate or solid-state form, subject to the equivalence language and other patent rights.

The fourth option is difficult if the approved product’s clinical performance depends on fasting administration. A generic applicant generally must demonstrate bioequivalence to the reference product, which may constrain meaningful changes to food instructions.

What other patents are likely to matter?

US 11,957,674 should be analyzed as one part of a broader paltusotine portfolio. Relevant patent families may cover:

  • The paltusotine chemical compound.
  • Salt and solvate forms.
  • Crystalline or amorphous solid-state forms.
  • Oral formulations.
  • Spray-drying processes.
  • Methods of treating acromegaly.
  • Methods of suppressing GH and IGF-1.
  • Neuroendocrine tumor treatment.
  • Combination treatment with other endocrine therapies.
  • Manufacturing and purification processes.

A freedom-to-operate review should compare each family by earliest priority date, claim type, jurisdiction, terminal disclaimer, continuation status, PTA, PTE eligibility and Orange Book listing. A single unexpired compound or formulation patent could block launch even if US 11,957,674 is invalidated.

How does paltusotine compare with competing acromegaly drugs?

Product or class Administration Competition profile
Paltusotine Oral small molecule Direct oral competition; method and formulation patents
Mycapssa, oral octreotide Oral peptide capsule Competes on oral convenience; separate formulation and peptide patent estate
Sandostatin LAR, octreotide Long-acting injection Established injectable standard
Somatuline Depot, lanreotide Long-acting injection Established injectable somatostatin analog
Somavert, pegvisomant Injection GH-receptor antagonist; different mechanism
Generic octreotide or lanreotide products Injectable Lower-cost alternatives where available

Paltusotine’s competitive differentiation is oral administration without injections. Its patent exposure is therefore tied to both the active ingredient and the oral delivery technology needed to achieve adequate exposure.

What revenue exposure does this patent create?

The patent directly protects revenue from paltusotine tablets used for acromegaly and potentially neuroendocrine tumors. The most valuable claims are likely claims 1, 2, 4, 5, 6 and 15 because they track ordinary product use rather than a narrow manufacturing configuration.

Revenue exposure depends on:

  • Number of treated acromegaly patients.
  • Net price relative to injectable somatostatin analogs.
  • Patient switching from injections.
  • Payer coverage.
  • Duration of therapy.
  • Use in neuroendocrine tumors.
  • Availability of non-infringing generic formulations.
  • Orange Book listing and litigation outcomes.

The SDD claims provide meaningful secondary protection. They may delay competition even if a generic avoids a narrow method claim, particularly if the reference product’s bioavailability depends on the claimed polymer system.

What patent litigation or settlement agreements affect the patent?

The supplied claim set does not identify litigation, a Paragraph IV notice, a settlement agreement or a license. A complete litigation conclusion requires review of PACER, district-court dockets, the Federal Circuit docket, USPTO prosecution records and FDA Orange Book updates.

No license is apparent from the patent claim language. Crinetics has been the principal developer of paltusotine, and the commercial risk analysis should distinguish an internal product portfolio from third-party licensing rights.

Key Takeaways

  • US 11,957,674 protects oral paltusotine treatment methods, not merely the molecule.
  • Claim 1 requires administration on an empty stomach at least 30 minutes before a meal.
  • Claims 2 and 3 cover acromegaly and neuroendocrine tumors.
  • Claims 4 and 15 cover approximately 20-60 mg of paltusotine hydrochloride equivalent.
  • Claims 5 and 6 cover once-daily administration, including administration with water before a meal.
  • Claims 7-14 protect spray-dried dispersions using HPMCAS or PVP/VA.
  • The highest generic risk arises from a product matching the commercial dose, label and SDD formulation.
  • Paltusotine is a small molecule, so biosimilar competition does not apply.
  • Future generic competition would most likely proceed through ANDA Paragraph IV litigation.
  • The patent should be analyzed with the broader compound, formulation, solid-state and manufacturing portfolio before estimating final exclusivity.

FAQs

Can a generic avoid US 11,957,674 by administering paltusotine with food?

Potentially, if the product is genuinely labeled and used with food and does not satisfy the claim’s empty-stomach limitation. That strategy may be constrained by bioequivalence requirements and the reference product’s approved food-effect instructions.

Does the patent cover every paltusotine tablet?

No. The broadest claim requires a covered oral treatment method and pre-meal administration. Claims 7-14 add specific SDD and polymer limitations. A paltusotine product using a different formulation may avoid the formulation claims but remain exposed to method claims and other patent families.

Is paltusotine subject to biosimilar competition?

No. Paltusotine is a small molecule. The relevant competition model is generic-drug competition through an ANDA, not biosimilar substitution under the Public Health Service Act.

Can a generic use a different polymer from HPMCAS or PVP/VA?

A different polymer may avoid the literal polymer limitations in claims 7-14. It would not automatically avoid claim 1 or other patents covering the compound, dose, indication, solid form or manufacturing process.

Is claim 6 broader than claim 15?

No. Claim 6 adds once-daily administration, a glass of water and the empty-stomach, 30-minute pre-meal condition. Claim 15 focuses on the 20-60 mg hydrochloride dose. Each claim has different limitations, and claim 6 is narrower in express scope.

References

  1. United States Patent and Trademark Office. (2024). U.S. Patent No. 11,957,674 B2.
  2. United States Code. (2023). 35 U.S.C. § 154: Contents and term of patent; provisional rights.
  3. United States Code. (2023). 21 U.S.C. § 355: New drugs.
  4. U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations.
  5. U.S. Food and Drug Administration. (2023). Orange Book: Approved drug products with therapeutic equivalence evaluations.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 11,957,674

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Crinetics PALSONIFY paltusotine hydrochloride TABLET;ORAL 219070-001 Sep 25, 2025 RX Yes No 11,957,674 ⤷  Start Trial TREATMENT OF ADULTS WITH ACROMEGALY WHO HAD AN INADEQUATE RESPONSE TO SURGERY AND/OR FOR WHOM SURGERY IS NOT AN OPTION ⤷  Start Trial
Crinetics PALSONIFY paltusotine hydrochloride TABLET;ORAL 219070-002 Sep 25, 2025 RX Yes Yes 11,957,674 ⤷  Start Trial TREATMENT OF ADULTS WITH ACROMEGALY WHO HAD AN INADEQUATE RESPONSE TO SURGERY AND/OR FOR WHOM SURGERY IS NOT AN OPTION ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 11,957,674

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 123453 ⤷  Start Trial
Australia 2021341936 ⤷  Start Trial
Canada 3191084 ⤷  Start Trial
Chile 2023000627 ⤷  Start Trial
China 116456968 ⤷  Start Trial
China 121943816 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.